Covered recipient · General Payments record
DANIEL P GOLIGHTLY
Allopathic & Osteopathic Physicians Family Medicine Addiction Medicine
General Payments · PY2018–2023
$2,155.35
- Reported across 112 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2023 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $377.47 | 18 |
By paying entity
PY2023 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $187.62 | 10 |
| ITI, Inc. | $96.78 | 4 |
| Axsome Therapeutics, Inc. | $32.93 | 1 |
| Supernus Pharmaceuticals, Inc. | $25.93 | 1 |
| Otsuka America Pharmaceutical, Inc. | $18.31 | 1 |
| Noven Therapeutics, LLC | $15.90 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2023 (18)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $26.45 | 02/13/2023 | Food and Beverage | Undisputed | 01/23/2026 | 997361407 | CMS |
| ABBVIE INC. | $14.61 | 02/20/2023 | Food and Beverage | Undisputed | 01/23/2026 | 997361409 | CMS |
| ABBVIE INC. | $24.96 | 03/10/2023 | Food and Beverage | Undisputed | 01/23/2026 | 997361411 | CMS |
| ABBVIE INC. | $16.94 | 04/17/2023 | Food and Beverage | Undisputed | 01/23/2026 | 997361413 | CMS |
| ABBVIE INC. | $16.94 | 04/21/2023 | Food and Beverage | Undisputed | 01/23/2026 | 997361415 | CMS |
| ABBVIE INC. | $22.97 | 05/31/2023 | Food and Beverage | Undisputed | 01/23/2026 | 997361417 | CMS |
| ABBVIE INC. | $21.26 | 06/10/2023 | Food and Beverage | Undisputed | 01/23/2026 | 997361419 | CMS |
| ABBVIE INC. | $14.64 | 08/25/2023 | Food and Beverage | Undisputed | 01/23/2026 | 997361421 | CMS |
| ABBVIE INC. | $5.57 | 10/17/2023 | Food and Beverage | Undisputed | 01/23/2026 | 997361423 | CMS |
| ABBVIE INC. | $23.28 | 10/31/2023 | Food and Beverage | Undisputed | 01/23/2026 | 997361425 | CMS |
| Axsome Therapeutics, Inc. | $32.93 | 01/10/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1056137855 | CMS |
| ITI, Inc. | $22.49 | 02/17/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1040541291 | CMS |
| ITI, Inc. | $24.88 | 03/04/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1040541299 | CMS |
| ITI, Inc. | $24.81 | 04/28/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1040541309 | CMS |
| ITI, Inc. | $24.60 | 08/01/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1040541315 | CMS |
| Noven Therapeutics, LLC | $15.90 | 02/15/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1028332666 | CMS |
| Otsuka America Pharmaceutical, Inc. | $18.31 | 06/12/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1014364157 | CMS |
| Supernus Pharmaceuticals, Inc. | $25.93 | 04/24/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1053251665 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023
- Generated from
- OP_DTL_GNRL_PGYR2023_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.